Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome

Background Although generic medications are approved based on bioequivalence with brand‐name medications, there remains substantial concern regarding their clinical effectiveness and safety. Lipitor®, available as generic atorvastatin, is one of the most commonly prescribed statins. Therefore, we compared the effectiveness of generic atorvastatin products and Lipitor®. Methods and Results We conducted a population‐based cohort study, using propensity score matching to minimize potential confounding of patients ≥65 years, discharged alive after acute coronary syndrome (ACS) hospitalization between 2008 and 2012 in Ontario, Canada, who were prescribed Lipitor® or generic atorvastatin within 7 days of discharge. The primary outcome was 1‐year death/recurrent ACS hospitalization. Secondary outcomes included hospitalization for heart failure, stroke, new‐onset diabetes, rhabdomyolysis, and renal failure. In the 7863 propensity‐matched pairs (15 726 patients), mean age was 76.9 years, 56.3% were male, 87.6% had myocardial infarction, and all patients had complete follow‐up. At 1 year, 17.7% of those prescribed generic atorvastatin and 17.7% of those prescribed Lipitor® experienced death or recurrent ACS (hazard ratio, 1.00; 95% CI, 0.93–1.08; P=0.94). No significant differences in rates of secondary outcomes between groups were observed. Prespecified subgroup analyses by age, sex, diabetes, atorvastatin dose, or admission diagnosis found no outcome difference between groups. Conclusions Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor® at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness.

[1]  G. Mancia,et al.  Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. , 2014, European journal of internal medicine.

[2]  T. Brennan,et al.  Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes , 2014, Annals of Internal Medicine.

[3]  Peter C Austin,et al.  A comparison of 12 algorithms for matching on the propensity score , 2013, Statistics in medicine.

[4]  R. Hegele,et al.  Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. , 2013, The Canadian journal of cardiology.

[5]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[6]  T. Hong,et al.  Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial. , 2013, Clinical therapeutics.

[7]  H. Krumholz,et al.  Generic atorvastatin and health care costs. , 2012, The New England journal of medicine.

[8]  P. Ravaud,et al.  Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic Review , 2011, PloS one.

[9]  R. Češka,et al.  Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. , 2011, International angiology : a journal of the International Union of Angiology.

[10]  William H Shrank,et al.  Physician Perceptions About Generic Drugs , 2011, The Annals of pharmacotherapy.

[11]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[12]  Hyo‐Soo Kim,et al.  Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. , 2010, Clinical therapeutics.

[13]  William H Shrank,et al.  Patients' perceptions of generic medications. , 2009, Health affairs.

[14]  M J Ball,et al.  Healthcare Informatics , 2009, Encyclopedia of Database Systems.

[15]  M Alan Brookhart,et al.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. , 2008, JAMA.

[16]  E. Halm,et al.  Beliefs about generic drugs among elderly adults in hospital-based primary care practices. , 2008, Patient education and counseling.

[17]  E. Antman,et al.  Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. , 2007, Health affairs.

[18]  Susan L Ettner,et al.  The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. , 2006, Archives of internal medicine.

[19]  Joel Lexchin,et al.  The effect of generic competition on the price of brand-name drugs. , 2004, Health policy.

[20]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[21]  V. Wiwanitkit,et al.  A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[22]  Janet E Hux,et al.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.

[23]  V. Wiwanitkit,et al.  LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects – a randomized crossover study, the first report from Thailand , 2002, BMC clinical pharmacology.

[24]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[25]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[26]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[27]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[28]  L. J. Wei,et al.  The Robust Inference for the Cox Proportional Hazards Model , 1989 .